A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- Guest Voice: A 150-mile Bike MS ride comes full circle
- Large study shows how 2 MS treatments stack up in the real world
- Multiple sclerosis has given me plenty of reasons to change my mind
- Probiotics may ease fatigue and pain in MS, review shows
- Scientists uncover immune cell clues behind Epstein-Barr virus link to MS